Published in Biotech Business Week, March 7th, 2005
The purchase price of $160 million, plus a 2-year earnout based on incremental sales growth in breast-related products, will be paid out of existing cash. This transaction is expected to close by the end of the first quarter and will be subject to customary closing conditions and clearance under the Hart-Scott Rodino Antitrust Improvements Act.
Proxima's lead product, the proprietary MammoSite Radiation Therapy System (RTS), is a...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Biotech Business Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.